AAX Biotech welcomes two new board members to elevate growth and development
AAX Biotech is pleased to welcome Svante Almkvist, an executive with a strong background in manufacturing of biopharmaceuticals, and Emmelie Persson, a PhD and leader in the pharmaceutical industry, as new board members.
AAX Biotech is a Swedish startup biotech company aiming to solve unmet needs in developing next-generation antibody therapeutics. The company’s two unique and patentable technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
Welcoming Svante Almkvist and Emmelie Persson into the Board of Directors marks an essential step in AAX Biotech’s strategic expansion. Their combined expertise in biopharmaceutical development and market strategy is primed to significantly accelerate the company’s growth, enhance its technological advancements, and strengthen its position in the global market.
Svante Almkvist's experience in the development and manufacturing of biopharmaceuticals, coupled with his entrepreneurial background, brings valuable insights. His expertise is expected to be instrumental in guiding AAX Biotech towards becoming a leading player in a growing market.
Emmelie Persson's extensive experience and knowledge in medical affairs and market access will bring a strong perspective in bridging the gap between innovative research and successful commercialization. Her background will enhance the company's strategy in navigating the complex biotech landscape.
“These appointments mark a significant milestone for AAX Biotech and are anticipated to play a vital role in the company’s growth and the development of our cutting-edge technologies, Seqitope™ and Opti-mAb™,” says Maria Lisa Knudsen, CEO of AAX Biotech. “We believe that the diverse expertise of our new board members will drive innovation and enhance our strategic initiatives in the evolving biotech landscape.”
This strategic expansion of the Board of Directors signifies AAX Biotech's commitment to innovation and excellence in the biotech field.
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
